{"id":10293,"date":"2026-05-22T17:00:00","date_gmt":"2026-05-22T15:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=7fc34468213652522dbdc51f94b58906"},"modified":"2026-05-22T17:00:00","modified_gmt":"2026-05-22T15:00:00","slug":"veracyte-to-host-investor-call-on-june-1-2026-to-discuss-asco-findings","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=10293","title":{"rendered":"Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings"},"content":{"rendered":"

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc.<\/a> (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that it will host a conference call and webcast on Monday, June 1, 2026 at 8:30 a.m. ET to discuss data from two significant phase III clinical trials using its Prosigna Breast and Decipher Prostate tests that will be presented at the 2026 ASCO Annual Meeting. This includes results from the OPTIMA and ENZAMET trials.<\/p><\/a><\/a>

\nProfessor Iain Macpherson, one of the principal investigators of OPTIMA, Professor of Breast Oncology at the University of Glasgow and Honorary Consultant Medical Oncologist at the Beatson West of Scotland Cancer Centre, will join for the discussion.<\/p>

\nThe conference call will be webcast live from the company\u2019s website and will be available via the following link: https:\/\/edge.media-server.com\/mmc\/p\/hexkn9gb<\/a>. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company\u2019s website at https:\/\/investor.veracyte.com\/events-presentations<\/a>.<\/p>

\nThe conference call dial-ins can be accessed by registering via this link<\/a>.<\/p>

\nAbout Veracyte<\/b><\/p>

\nVeracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company\u2019s molecular tests assess the unique biology of each patient\u2019s tumor to help clinicians answer essential questions about cancer care. Veracyte\u2019s Diagnostics Platform<\/a> combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development<\/a>. The company\u2019s portfolio includes the Afirma\u00ae Genomic Sequencing Classifier test<\/a>, Decipher\u00ae Bladder Genomic Classifier test<\/a>, Decipher\u00ae Prostate Genomic Classifier test<\/a>, Prosigna\u00ae Breast Risk of Recurrence test<\/a>, and the TrueMRD\u2122 Monitoring Test for MIBC<\/a>. For more information, visit Veracyte\u2019s website<\/a> or follow the company on LinkedIn<\/a> or X (Twitter)<\/a>.<\/p> Contacts<\/b>

\nInvestors:<\/b>Kelly Gura\ninvestors@veracyte.com<\/a><\/p>

\nMedia:<\/b>Molly Cornbleet\nmedia@veracyte.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that it will host a conference call and webcast on Monday, June 1, 2026 at 8:30 a.m. ET to discuss data from two signific…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-10293","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/10293","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10293"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/10293\/revisions"}],"predecessor-version":[{"id":10294,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/10293\/revisions\/10294"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10293"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10293"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10293"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}